Gilde Healthcare Expands Team by Appointing Bob Silverman as Operational Partner

Utrecht, the Netherlands and Boston, USA – Gilde Healthcare, an investment firm focused on private healthcare companies, today announced that Bob Silverman has been appointed as Operational Partner. His main focus will be on supporting Gilde’s investments in diagnostics and medical devices.

Mr. Silverman served as the CEO of mtm Laboratories AG, an in-vitro diagnostics company which developed and commercialized a portfolio of products for early detection and diagnosis of cervical cancer. He was instrumental in building mtm into a global, fully integrated commercial business. In 2009 Gilde provided growth capital to mtm to finance its commercial activities. Mr. Silverman successfully negotiated the purchase of mtm by Roche Diagnostics in August 2011 for a total deal value of €190 Million and then facilitated the integration of mtm into Roche.

Prior to leading mtm laboratories, he was the Senior Vice-President of Worldwide Commercial Operations for Viacell, a company focused on developing stem cell therapies and cord blood banking. Before this, he spent 6 years with Cytyc Corporation. During his tenure at Cytyc, he served as the Vice President of Marketing and the Vice President of International, and was integral in launching and establishing the core technology (the ThinPrep Pap Test) into the standard of care for cervical cancer screening. Previous positions include Vice-President of Marketing for Pasteur Merieux Connaught, Director of New Product Development for Abbott Laboratories Pharmaceutical Products Division and Management Consultant with Bain and Company. He earned his Master’s degree in Marketing and Finance from Northwestern’s Kellogg Graduate School of Management and received his Bachelor of Science degree in Pharmacy from the University of Michigan. He currently works with several companies in a Board and Advisory capacity.

About Gilde Healthcare

Netherlands-based Gilde Healthcare is a transatlantic investment firm focused on private healthcare companies. Gilde has over €450 million under management and invests in the areas of diagnostics, medical devices, therapeutics and healthcare services.

For a list of Gilde’s portfolio companies please visit the website at